Atypical hemolytic uremic syndrome (aHUS) is the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. Advances in the past 15 years have shown aHUS to be a disorder of the alternative pathway of complement. Mutations in the complement-regulatory proteins factor H ( CFH ), factor I ( CFI ), and membrane cofactor protein ( CD46 ; MCP) and complement components factor B ( CFB ) and C3 all result in complement overactivation. 1 Genetic screening of people with aHUS is now in mainstream clinical practice and provides important prognostic information that guides clinical decision making. With increasing genetic analysis, genotype -phenotype correlations have emerged. For instance, in patients with mutations in CFH there is a very poor prognosis; 60 -70 % of patients die or reach end-stage renal failure within a year. In comparison, those with CD46 mutations of podocyte-expressed proteins might yield a richer and more informative view of podocyte injury and loss.
Th e study of Fukuda et al. 7 also raises the question of whether it is possible that, if initial therapy in human disease can limit early podocyte losses to less than a certain threshold, 13 inexorable progression to renal failure may be avoided. Conversely, if this is not possible, will it always be the case that aggressive enough angiotensin blockade (possibly, targeted to minimize urinary podocyte excretion) will be sufficient to preserve glomerular architectural stability, protect remnant podocytes, and assure long-term renal survival?
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The author declared no competing interests. have a better outcome, with about 80 % remaining dialysis-independent. 2 The genetic defect can also predict the aHUS recurrence rate aft er renal transplantation. 3 Th e complement-regulatory defect in those with mutations in the membranebound CD46 is corrected by an allograft bearing wild-type CD46 . In those with mutations in the serum complement regulators CFI and CFH , which are produced by the liver, a renal transplant does not correct the defect, so the recurrence rate is high. Th us genetic screening determines the suitability for isolated renal transplantation, combined liver -kidney transplantation, or the prophylactic use of eculizumab for transplantation. Mutation screening in aHUS is challenging because most of the diseaseassociated mutations are individually rare ( Figure 1 ) . In most cases, interpretation of the functional signifi cance of nonsense mutations, large gene rearrangements, and frameshift mutations is clear-cut. However, a signifi cant proportion of variants consist of missense mutations or potential splicesite changes of uncertain biologic or clinical relevance. Th ese variants of unknown signifi cance (VUSs) pose a challenge in reporting the genetic results. In these settings numerous lines of evidence may be used to assess the probability that a genetic variant may be relevant to disease.
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Th is can be done by searching of locusspecifi c databases for information on previously described genetic variants (for example, the FH aHUS Mutation Database; www.fh -hus.org / ). Th e use of ethnically matched controls is also a common mechanism to eliminate genetic variants as pathogenic. Species conservation analysis and in silico prediction of the severity of amino acid changes or splice-site prediction are also used. Th e defi nitive interpretation of a VUS is oft en dependent on a reliable functional assay; however, these tests are too costly and time-consuming to be used in a diagnostic screening service and usually rely on allied research groups. Th is has been the case for CFH mutations in aHUS.
Factor H is composed of 20 complement control protein (CCP) modules. It is the most important fl uid-phase regulator of the alternative pathway. It competes with factor B for C3b binding, accelerates the decay of the C3 convertase into its components, and acts as a cofactor for factor I-mediated proteolytic inactivation of C3b ( Figure 1 ). Th ese functions are mediated through the N-terminal four CCPs (CCP1 -4). Factor H also regulates complement on host cells by binding to the glycosaminoglycans of endothelial cells and exposed basement membranes via its carboxyl-terminal domains (CCP19 -20) .
Th e majority of mutations in CFH in aHUS are heterozygous and are located in exons encoding the C-terminal domain of the protein, which is responsible for mediating complement protection of the cell surface ( Figure 1 ). Th ese mutations do not usually result in a quantitative defi ciency of factor H. Functional analysis of these mutations has revealed impaired complement regulation at the cell surface. 4, 5 A few mutations in the N-terminal region of CFH have been reported, and functional analysis has revealed that they are defective in their ability to control the alternative pathway both in the fl uid phase and on the cell surface. 6 VUSs have been described in the intervening CCPs of factor H ( Figure 1 ) , although a lack of functional analysis has resulted in an inability to predict their likely functional consequences.
Tortajada et al. 7 (this issue) now provide compelling genetic and functional evidence suggesting that two genetic VUSs, I890 and L1007, previously reported in aHUS, may not play a role in disease pathogenesis. Th ey demonstrate that the frequency of the I890 and L1007 variants is not signifi cantly diff erent in control and patient populations. Further genetic analysis demonstrated that these variants form part of an infrequent ancient CFH haplotype in white peopleprobably of African origin, given the high frequency in sub-Saharan African and African-American populations. Th ese variants did not aff ect the factor H level in plasma. Functional analysis revealed that these variants in CCPs 15 (I890) and 17 (L1007) did not aff ect binding to C3b. Th is would be consistent with previous mapping studies of factor H binding 8 co-crystal structures of factor H with C3 fragments. 9, 10 In keeping with this, fl uidphase cofactor assays and cell-surface hemolytic assays do not reveal any defect in complement regulation. Thus, although this study does not demo nstrate any functional signifi cance of these genetic variants, the importance of these results is not diminished. Publication bias will oft en see negative studies neglected and unpublished. Th is study is a fi ne example of the importance of the good negative study to the wider scientifi c and medical communities. Using this information, genetic screening laboratories will be able to provide more precise information as to the signifi cance of these VUSs. It also highlights the importance of revisiting past genetic data in the light of new evidence. People previously demonstrated to have these VUSs can now be reassured that these changes are not causative, while clinicians can modify their decisions in the sure knowledge that these variants are not pathogenic.
Th e increasing amount of genetic data produced by the latest generation of sequencing technology oft en surpasses our ability to accurately interpret it. In this setting, the publication of welldesigned functional studies of VUSs, even when nega tive such as that by Tortajada et al. , 7 is vital to screening laboratories.
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